Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.12 p
-0.02 p(-10.97%)
At close: 4:00 PM EDT
0.12 p
-0.02 p(-10.97%)
Day’s Range― - ―
52-Week Range0.10 p - 0.39 p
Previous CloseN/A
Volume29.11M
Average Volume (3M)23.36M
Market Cap
£8.29M
Enterprise Value11.32M
Total Cash (Recent Filing)£1.72M
Total Debt (Recent Filing)£75.00K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Jun 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding7,899,737,000
10 Day Avg. Volume42,965,088
30 Day Avg. Volume23,363,690
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces fixed financial obligations and refinancing exposure, giving Solvonis greater flexibility while it addresses operating challenges. This balance-sheet structure can help preserve solvency and leave more options for funding development or restructuring over the next several quarters.
Positive, Improving Equity BaseA positive and expanding equity base provides a stronger capital cushion than a balance sheet already impaired by accumulated deficits. Although it does not resolve losses, this resilience can support continued operations and reduce immediate balance-sheet stress over the medium term.
Cash Burn Broadly Reflects Reported LossesThe close relationship between reported losses and cash consumption suggests the cash-flow deficit is not being amplified by a materially worse underlying cash conversion pattern. That gives management clearer visibility into the main funding issue, even though operating cash generation remains negative.
Bears Say
Persistent Operating And Net LossesRecurring operating and net losses indicate that the business has not yet demonstrated a sustainable earnings engine. Continued losses can consume the equity cushion, limit internally funded investment, and make future development dependent on external financing or a material improvement in operations.
Revenue Has Effectively DisappearedRevenue falling to effectively zero in the latest annual periods removes evidence of commercial scale and makes margin trends uninformative. Without a durable revenue base, Solvonis has limited support for recurring cost coverage, operating leverage, or a credible path toward sustainable profitability.
Persistent And Worsening Cash BurnOngoing negative operating cash flow and worsening free cash flow increase the amount of funding required to sustain the company. If this pattern continues, cash resources and equity may face further pressure, reducing flexibility to invest in development or absorb execution setbacks.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest share price was 0.10 p and its highest was 0.39 p in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is £8.29M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Jun 30, 2027 which is in 261 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Sep 30, 2026. The company reported 0 p earnings per share for the quarter.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 7,899,737,000 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of 0 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―